Clincosm LogoSign in Get a demo

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

Sponsor
National Cancer Institute (NCI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00042861
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining UCN-01, fluorouracil, and leucovorin in treating patients who have metastatic or unresectable solid tumors.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

OBJECTIVES:

  • Determine the maximum tolerated dose of fluorouracil when given in combination with UCN-01 and leucovorin calcium in patients with metastatic or unresectable solid tumors.

  • Determine the clinical toxic effects of this regimen in these patients.

  • Determine the pharmacokinetics of these drugs in these patients.

  • Correlate, if possible, the pharmacokinetics of these drugs with clinical toxicity in these patients.

  • Assess the pharmacodynamic effects of these drugs in these patients.

  • Assess any clinical activity of this regimen in patients with measurable disease.

OUTLINE: This is a dose-escalation study of fluorouracil (5-FU).

Patients receive leucovorin calcium (CF) IV over 2 hours and 5-FU IV (at the midpoint of CF administration) on day 1, followed by UCN-01 IV over 36-72 hours, on weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The recommended phase II dose (RPIID) is defined as the dose preceding the MTD. At least 6 additional patients are treated at the RPIID.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 16 months.

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin
Study Start Date :
Aug 1, 2002

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    DISEASE CHARACTERISTICS:

    • Histologically confirmed solid tumor that is metastatic or unresectable and for which no standard curative or palliative measures exist or are effective

    • No brain metastases or primary CNS malignancy

    PATIENT CHARACTERISTICS:

    Age

    • 18 and over

    Performance status

    • ECOG 0-2

    Life expectancy

    • Not specified

    Hematopoietic

    • Absolute neutrophil count at least 1,500/mm3

    • Platelet count at least 100,000/mm3

    Hepatic

    • Bilirubin no greater than 1.5 mg/dL

    • AST and ALT no greater than 3 times upper limit of normal

    Renal

    • Creatinine no greater than 1.5 mg/dL OR

    • Creatinine clearance at least 60 mL/min

    Cardiovascular

    • No known active coronary artery disease

    Pulmonary

    • No pulmonary dysfunction

    Other

    • HIV negative

    • No history of unusually severe and/or prolonged toxicity during prior therapy with fluorouracil (5-FU) or 5-FU prodrugs

    • No diabetes mellitus requiring insulin or oral hypoglycemic therapy

    • No ongoing or active infection requiring IV antibiotics

    • No other serious concurrent medical illness that would preclude study

    • No psychiatric illness or social situations that would preclude study

    • Not pregnant or nursing

    • Negative pregnancy test

    • Fertile patients must use effective contraception

    PRIOR CONCURRENT THERAPY:

    Biologic therapy

    • At least 4 weeks since prior immunotherapy and recovered

    • No concurrent cytokines during the first course of therapy

    Chemotherapy

    • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

    Endocrine therapy

    • No concurrent systemic corticosteroids

    Radiotherapy

    • At least 2 weeks since prior radiotherapy and recovered

    • No prior pulmonary or mediastinal radiation exceeding 40 Gy

    Surgery

    • Recovered from prior surgery

    Other

    • No other concurrent investigational agents

    • No concurrent cimetidine

    • No concurrent sorivudine or brivudine

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda Maryland United States 20892-1182

    Sponsors and Collaborators

    • National Cancer Institute (NCI)

    Investigators

    • Study Chair: Jean L. Grem, MD, National Cancer Institute (NCI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00042861
    Other Study ID Numbers:
    • CDR0000069478
    • NCI-NAVY-01-04
    • NCI-5535
    • NCI-02-C-0222
    • NCT00039637
    First Posted:
    Jan 27, 2003
    Last Update Posted:
    Apr 30, 2015
    Last Verified:
    Apr 1, 2003
    Keywords provided by , ,
    unspecified adult solid tumor, protocol specific
    Additional relevant MeSH terms:
    Leucovorin
    Fluorouracil
    7-hydroxystaurosporine
    Calcium
    Levoleucovorin

    Study Results

    No Results Posted as of Apr 30, 2015